76.33
1.42 (1.90%)
| Previous Close | 74.91 |
| Open | 74.50 |
| Volume | 290,271 |
| Avg. Volume (3M) | 961,596 |
| Market Cap | 5,189,993,984 |
| Price / Earnings (TTM) | 31.67 |
| Price / Earnings (Forward) | 13.93 |
| Price / Sales | 3.43 |
| Price / Book | 4.44 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Profit Margin | 16.55% |
| Operating Margin (TTM) | 27.38% |
| Diluted EPS (TTM) | 3.51 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Quarterly Earnings Growth (YOY) | -44.30% |
| Total Debt/Equity (MRQ) | 52.78% |
| Current Ratio (MRQ) | 5.74 |
| Operating Cash Flow (TTM) | 525.08 M |
| Levered Free Cash Flow (TTM) | 241.87 M |
| Return on Assets (TTM) | 14.39% |
| Return on Equity (TTM) | 24.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Lantheus Holdings, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 2.24% |
| % Held by Institutions | 116.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Carmignac Gestion | 31 Dec 2025 | 1,122,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 89.00 (Truist Securities, 16.60%) | Buy |
| Median | 85.00 (11.36%) | |
| Low | 85.00 (Mizuho, 11.36%) | Buy |
| 85.00 (Citizens, 11.36%) | Buy | |
| Average | 86.33 (13.10%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 75.38 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 02 Mar 2026 | 89.00 (16.60%) | Buy | 76.32 |
| 18 Dec 2025 | 82.00 (7.43%) | Buy | 64.84 | |
| Citizens | 27 Feb 2026 | 85.00 (11.36%) | Buy | 74.91 |
| 24 Feb 2026 | 78.00 (2.19%) | Buy | 73.61 | |
| Mizuho | 27 Feb 2026 | 85.00 (11.36%) | Buy | 74.91 |
| 17 Dec 2025 | 72.00 (-5.67%) | Buy | 65.24 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |